Navigation Links
Hovione's TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza
Date:4/15/2009

LOURES, Portugal, April 15 /PRNewswire/ -- Hovione is pleased to announce that its licensee Daiichi Sankyo (Tokyo, Japan) has informed that it intends to use Hovione's TwinCaps(R) dry powder inhaler device in the launch of the compound CS-8958, an inhaled long-acting neuraminidase inhibitor active against the influenza virus. Daiichi Sankyo has completed patient enrolment for Phase III clinical trials in Japan and other Asian countries and results are expected to be released mid year, including data to confirm the device switching. TwinCaps(R) was specifically developed by Hovione for the indication and licensed to Daiichi Sankyo and Biota Holdings Ltd (Victoria, Australia).

The announcement follows the recent publication(1) of data indicating that the compound is as effective as Relenza(R) and Tamiflu(R) against various influenza strains. Significantly this efficacy is achieved with a single dose, as opposed to a treatment over five days for the established drugs.

A 20 mg dose of CS-8958 is inhaled from powder compartments in the TwinCaps(R) inhaler, which is made of just two plastic parts. Hovione believes this is currently the simplest inhaler being tested in clinical trials and once approved, will be the simplest in the market and have the lowest cost of goods. TwinCaps(R) has no moving parts to deaggregate the dose of powder and only requires a low inspiratory airflow to achieve optimal delivery to the lung. This means that children and the elderly will find it easier to inhale the full dose.

The design challenge for Hovione was to make TwinCaps(R) extremely simple to use, as in the case of a pandemic requiring immediate treatment of large populations, there is an obvious advantage for simple operation. The TwinCaps(R) DPI (to be manufactured in Japan and Europe) is a two-piece unit comprising body and shuttle components. The shuttle has two pre-filled dose chambers, left and right. I
'/>"/>

SOURCE Hovione
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDoses Electronic Dry Powder Inhaler
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
7. Phase III Trial Finds Pharmaxis Bronchitol Effective
8. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
9. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., BOCARATON,Fla.,Nov.25/PRNewswire/--Formanybusin...Thenation,slargestandfastestgrowingnetworkofexpert...ised bioidenticalhormones has grownthenumberof p...36physicians -andisinprogresstoaddmorephysician-ow...year. ,, Inthepastyear ,BodyLogicMDhasopened13n...
(Date:11/24/2009)...e is available in German . , Whether it,s C...FID tags (Radio Frequency Identification) are incr...y make it possible to label objects or goods and i... appropriate scanner can read and process the data...ed to goods under production conditions of up to 1...
(Date:11/24/2009)...YandBLENHEIM,Ontario,Nov.24/PRNewswire-FirstCall/-...heassetsofHylandSeeds,adivisionofThompsonsLimitedo...herexpandDowAgroSciences,currentseedsbusinessasthe...in 2010 andDowAgroSciencesHerbicideTolerantTrait...ctedinthenearfuture. ,, "Thisacquisitionbringst...
(Date:11/24/2009)...AI,Nov.24/PRNewswire-Asia/--NODPharmaceuticalsInc....llowedthepatentapplicationfor,itsnano-particleoral...ghlyefficientapproachtoincorporatepeptidesor,prote...eryofdrugs,otherwiseadministeredasinjections.NODte...nymacromoleculardrugssuchasinsulin,interferon,gro...
Breaking Biology Technology:Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Intelligence inside metal components 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3
...ompany Reports Quarterly Net Income of $536,000 , ...l, Inc. (OTC Bulletin Board: CCEL) (the "Company"... family cord blood banks, today announced results ...nsolidated revenues for the first quarter of fisca... approximately $4.2 million for the first quarter ...
... Millennium Bioceutics, announces the...Caplex, to cancer patients worldwide. Caplex con...by an Oncologist and Clinical Dietitian. Caplex n...prehensive source of the most effective anti-tumor...ccumulated from medical research. Impressive chang...
...ina, April 8 Sinobiopharma Pharmaceutical Group (...he appointment of Ms. Yan Tan as Director of Marke...n Pharmaceutical Co., Ltd., Netherlands. She serve...anon, which was recently sold to Schering-Plough. ...nagement roles at China National Medicines Corpora...
Other Biology Technology:Cryo-Cell International, Inc. Reports First Quarter 2009 Results 2Cryo-Cell International, Inc. Reports First Quarter 2009 Results 3Cryo-Cell International, Inc. Reports First Quarter 2009 Results 4Cancer Fighting Nutrition Supplement, Caplex, Offers Cancer Patients A New All-Natural Treatment Option 2Sinobiopharma, Inc. Appoints New Director of Marketing 2
(Date:11/25/2009)..., On September 11, firefighters, police officers ...fort in the World Trade Center complex. They battl... searched for survivors, tackled fires and evacuat...ontained an estimated 17,000 people. And making th...nications: frightened workers and their relatives ...
(Date:11/25/2009)..., LA JOLLA, CAWhen you eat may be just as vital... at the Salk Institute for Biological Studies. The...ing and waning of thousands of genes in the livert...led by food intake and not by the body,s circadian...ding time determines the activity of a large numbe...
(Date:11/24/2009)..., Stents that keep weakened and flabby arteries f...er six months, those stents are no longer needed -...unnecessary. Previously, doctors had no choice but...n of Tel Aviv University,s Department of Biomedica...iber platform that carries drugs where they,re nee...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3A coating for life 2Analysis of Congressional health reform bills highlights similarities differences costs 59991 1Analysis of Congressional health reform bills highlights similarities differences costs 59991 2Sex based prenatal brain differences found 10503 1Sex based prenatal brain differences found 10503 2Wildlife Conservation Society to expand health surveillance through PREDICT 10501 1Wildlife Conservation Society to expand health surveillance through PREDICT 10501 2Wildlife Conservation Society to expand health surveillance through PREDICT 10501 3
...sher for Physics, Mathematics and Computer Science...ERN and DESY high-energy physics laboratories. Un...lly cover article-processing charges for all resea...eviewed open access journal, PMC Physics A. , PMC...versity of Oxford and Royal Holloway and was launc...
...ircuits with brains are under intensive developmen...pplication in many areas, according to a study jus...ger of the University of Southern California chair...International Assessment of Research and Developme...ober by the World Technology Evaluation Center, In...
...chers at Hasbro Childrens Hospital, the pediatric ... Hospital, New York, offers new insight into the r...elopment of gastrointestinal disease. , The cysti...TR) gene codes for a protein also known as CFTR. M...c fibrosis (CF) and a range of digestive diseases,...
Other Biology News:Top physics laboratories sign up to open access with PhysMath Central 2Brain-computer link systems on the brink of breakthrough, study finds 2Study uncovers clues to cystic fibrosis gene dysfunction and gastrointestinal disease 2
...e™ Agarose Gel-Digesting Preparation contains...d at EPICENTRE for simple, quantitative recovery o...agarose gels following electrophoresis in TAE, TBE...ted directly in the TAE, TBE, MOPS, and phosphate ...
...nal deoxynucleotidyl transferase (TdT) is an intra... cortical thymocytes and minor subpopulation of bo...nzyme and increased numbers of TdT cells are found...as and lymphomas. Presence of TdT thus provides a ...
Ovine IFN Tau from PBL InterferonSource
...o has established an expertise in the forefront of...rt synthesis and synthesis in solution. , Our Fu...try and analytical HPLC at no extra cost, thus we ... standard. , Our team of expert peptide scien...
Biology Products: